For Q2 FY2024 (ended June 30, 2024), NIKA PHARMACEUTICALS, INC reported revenue of $156 and a net loss of $13,359. Operating loss was also $13,359, with diluted EPS of $0.00. The net loss increased approximately 3.2% year-over-year.
•Revenue was $156 for Q2 FY2024.
•Net loss of $13,359, up 3.2% from prior year.
•Operating loss matched net loss at $13,359.
•Diluted EPS was $0.00.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Nika Pharmaceuticals provides the development and distribution pharmaceutical products for dietary supplements and antiviral drugs in the United States. The company offers ITV-1, TNG, physiolong, carotilen, fructin, dry boza, anthocylen C, hypocholestin, biodetoxin, silymaron, and solamentum products.
Formerly known as Centennial Growth Equities Inc., the company rebranded as Nika Pharmaceuticals, Inc. in May 2022. Nika Pharmaceuticals, Inc. was incorporated in 2000 and is based in Henderson, Nevada.
Nika Pharmaceuticals Inc. is a healthcare company focused on the development and distribution of pharmaceutical products, specifically dietary supplements and antiviral drugs, in the United States. Its product portfolio includes ITV-1, TNG, physiolong, carotilen, fructin, dry boza, anthocylen C, hypocholestin, biodetoxin, silymaron, and solamentum. The company operates within the drug manufacturers - specialty & generic industry. Formerly known as Centennial Growth Equities Inc., it rebranded to Nika Pharmaceuticals Inc. in May 2022. The company was incorporated in 2000 and is based in Henderson, Nevada.
On which exchange is Nika Pharmaceuticals (NIKA) listed and what currency is used?
Nika Pharmaceuticals Inc. is listed on the OTC Markets OTCQB exchange under the ticker symbol NIKA. The OTCQB is a venture market for early-stage and developing U.S. and international companies. Trading is conducted in U.S. dollars (USD), which is the official currency of the United States. As an OTC-listed stock, NIKA may have different liquidity and reporting requirements compared to major exchanges like NYSE or Nasdaq. Investors should be aware of the risks associated with trading OTC securities.
What sector and industry does Nika Pharmaceuticals (NIKA) belong to?
Nika Pharmaceuticals Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This industry includes companies that develop and produce specialty drugs, generic medications, and over-the-counter products. As a specialty and generic drug manufacturer, Nika focuses on niche therapeutic areas such as dietary supplements and antiviral drugs. The company's products address various health needs, including cholesterol management (hypocholestin), detoxification (biodetoxin), and liver support (silymaron). The healthcare sector is highly regulated, and companies like Nika must comply with FDA and other regulatory standards.
Where is Nika Pharmaceuticals (NIKA) headquartered and what markets does it serve?
Nika Pharmaceuticals Inc. is headquartered in Henderson, Nevada, United States. The company primarily serves the U.S. market, as indicated by its focus on the development and distribution of pharmaceutical products within the country. Henderson is a city near Las Vegas, and the company's incorporation dates back to 2000. While the headquarters is in Nevada, the company's products are likely distributed across the United States. There is no information suggesting international operations. The company's region is classified as 'us', confirming its primary market is the United States.